News | Radiopharmaceuticals and Tracers | September 17, 2015

Event gathered international and domestic policy and technical experts to discuss progress on domestic production of valuable radioisotope without use of highly enriched uranium

Novation, Mo-99, NNSA 2015 meeting, reliable supplies, domestic production

September 17, 2015 — At the National Nuclear Security Administration’s (NNSA) 2015 Mo-99 Topical Meeting, Novation offered its support of efforts to encourage the adoption of processes to create a reliable domestic supply of non-highly enriched uranium (HEU) molybdenum-99 (Mo-99).

The meeting, hosted by Argonne National Laboratory and held in Boston Aug. 31-Sept. 3, brought together international and domestic policy and technical experts to present and discuss progress toward achieving the production of Mo-99 without the use of HEU.

When it comes to determining how the heart is functioning or whether cancer is present, doctors and patients rely on diagnostic tests using a radioactive medical-grade isotope made from Mo-99. Mo-99 is historically produced using HEU, an extremely dangerous substance used in nuclear weapons.

Leah Gannon, MBA, radiopharmaceutical portfolio executive for Novation, represented the company at the meeting. “Radiopharmaceuticals play a key role in the diagnosis of various disease states and have a complex and fragile supply chain. It was an honor to participate in the topical meeting to provide information around the barriers to entry in implementing non-HEU Mo-99 into the healthcare supply chain and propose an action plan to overcome those barriers,” said Gannon.

In her role at Novation, Gannon has worked on numerous imaging initiatives with a specific emphasis on radiopharmaceutical distribution and contrast media utilization. She also works with multidisciplinary provider councils and task forces and is an active member of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Association for Medical Imaging Management (AHRA).

Novation is committed to helping with the non-proliferation of HEU use in the production of radiopharmaceuticals as well as to helping the provider members it serves manage appropriate use of these medical isotopes. The company’s efforts include sharing best practices, providing active assistance with the development of successful programs, educating members on key medical imaging topics, and using institutional data to drive appropriate change in practice.

For more information: www.novationco.com


Related Content

News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
News | PET Imaging

February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...

Time February 09, 2024
arrow
News | Interventional Radiology

February 6, 2024 — RenovoRx, Inc., a clinical-stage biopharmaceutical company developing novel precision oncology ...

Time February 06, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
News | Radiology Business

January 23, 2024 — Bayer announced Nelson Ambrogio as the new Head of the Radiology Business at its Pharmaceuticals ...

Time January 23, 2024
arrow
Subscribe Now